Curanex Pharmaceuticals Inc CURX PHARMA
Company Overview
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +25.37% |
| 6 Months: | -33.68% |
| 3 Months: | -17.38% |
| 1 Month: | +29.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CURX Curanex Pharmaceuticals Inc PHARMA | 5.04 | -0.68 | $7.90M | 0.00% | -37.04% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | -44.20K | -93.30K | -137.45K | -57.66K | -951.33K | -3.18M |
| Net Income | -80.20K | -44.20K | -91.17K | -137.58K | -60.35K | -954.06K | -3.15M |
| Diluted EPS | - | -0.02 | -0.04 | -0.01 | 0.00 | -0.04 | -0.11 |
| R&D Expense | - | - | - | - | - | 677.47K | 2.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -365.06K | -4.24M |
| Net Income | -361.51K | -4.23M |
| Diluted EPS | -0.03 | -0.17 |
| R&D Expense | - | 2.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 517.93K | 11.58M |
| Total Equity | 60.09K | 503.36K | 11.22M |
| Cash & Equivalents | - | - | 5.00M |
| Total Liabilities | - | 14.57K | 361.04K |
| Current Liabilities | - | 14.57K | 137.03K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -555.58K | -10.48M |
| Financing Cash Flow | 630.10K | 15.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -71.8% | -37.7% |
| ROCE % | -72.5% | -37.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 0.30% | 4.76K | $20.96K |
| 2 | Renaissance Technologies, LLC | 0.17% | 2.60K | $11.44K |
| 3 | Virtu Financial LLC | 0.16% | 2.56K | $11.27K |
| 4 | Geode Capital Management, LLC | 0.12% | 1.91K | $8.42K |
| 5 | Jane Street Group, LLC | 0.10% | 1.56K | $6.87K |
| 6 | Two Sigma Investments, LP | 0.09% | 1.37K | $6.02K |
| 7 | Susquehanna International Group, LLP | 0.05% | 733 | $3.23K |
| 8 | Ground Swell Capital, LLC | 0.04% | 632 | $2.78K |
| 9 | Citigroup Inc. | 0.03% | 448 | $1.97K |
| 10 | UBS Group AG | - | 76 | $334 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CURX
Curanex Pharmaceuticals regains Nasdaq compliance after 1-for-20 reverse split - tradingview.com
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOeUlRbVNYOU95dDlJc1FOOVRmYjY2R1ktZmhzbmxodnZyUElEMldsSU5QZTRGSnZBaEhIZkN1QnhySGNSUklTYWY3NDY3SGxhSVJldkpVVTZXSHZJUzVremJFWVJGcUN5bVlBck1CZUViMmMxWlNMejJ5ZVhIX2pnbkI3V1R5M0JaRDlOcU…
Curanex Pharmaceuticals Inc Common Stock (NASDAQ: CURX) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9zblU1OThIbWxnLVF5Q28wOV9DVkpad1AxRDRsVjZRUGhEMFVNY0dFQVJsTlZKeW1rYV80cEVZeXRxcHE5U2RkS29MYnBQb1dPd2RtRllR?oc=5" target="_blank">Curanex Pharmaceuticals Inc Common Stock (NASDAQ: C…
Curanex Pharmaceuticals Inc (CURX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPZXN2UTZFMWFwTW5iamJ5ODhTZk9RMjVLYnRNYlhBS2dyOUsxX2MxR2tpT0c1UTZDU1lVNjVqY0NZdk42akNaX04xWkI0LWhnY3ZiNTFjUXU3b1F1TUFUeDI4WjJJSzlvSzlYbFJ6bng4MTI3WmZyU1c1OG16Z2k2Znl3MktWY2hCQ05tOV…
CURX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9kdHhuUm1kc1A2X2VIY05GVjl4Y0FxZW8xYmFWZG9nMGtFSUNVYUpTTHdxLWtNQ1NwOGpkaU04V1JxZFF2OEE?oc=5" target="_blank">CURX</a> <font color="#6f6f6f">Finviz</font>…
T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace - European Biotechnology Magazine
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQRVViV3ZTNnpsVTVxT1pZRkc0UlF1Q3pJTENGOUpndl9GcjNsWS14Ml84RUJUUHBCN1U5ZU5ySjVObWJ6NHE0cHNKTFFvM0x5Sk5pYzBnRmhxTWxpamw1NzFOMkMtM3lvV1BKVlhNMjREZjZtYXUxZjJKTVROdUMzZndR?oc=5" target=…
Net Worth Update: Senator Ted Cruz Made an Estimated $540.7K in the Stock Market Last Month - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNd2pMRUZVNXI0NWFtM1ZXV1dkWGoxc0xfblRpMUV1V0FQUFF0M1VYbzBlVUd5SktIb2lISk9fcTVXbC01NVZCQkJzZnRoN3RrOHY0dlhpTjhyemdLWG56N2FSeV9PSll2YXNveVdvQm9rNy1taDJPMjB5SkhjQ056S1MtMFhZeElmVjVzZU…
CURX — Frequently Asked Questions
What is the current share price of Curanex Pharmaceuticals Inc (CURX)?
As of 2026-09-19 21:16 PDT, Curanex Pharmaceuticals Inc (CURX) trades at $5.04 on NasdaqCM. Its 52-week range is $3.66 to $183.20.
What is the market capitalisation of CURX?
Curanex Pharmaceuticals Inc (CURX) has a market capitalisation of $7.90M on NasdaqCM.
What is the P/E ratio of CURX?
CURX trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.24.
Is CURX a good stock to buy?
This page provides a data-driven analysis of Curanex Pharmaceuticals Inc (CURX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.